{
    "root": "48a98150-1118-4dab-8637-80ad223e24a2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dicyclomine Hydrochloride",
    "value": "20250320",
    "ingredients": [
        {
            "name": "DICYCLOMINE HYDROCHLORIDE",
            "code": "CQ903KQA31"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        }
    ],
    "indications": "dicyclomine hydrochloride indicated treatment patients functional bowel/ irritable bowel syndrome .",
    "contraindications": "must adjusted individual patient needs .",
    "warningsAndPrecautions": "dicyclomine hydrochloride tablets , usp available containing 20 mg dicyclomine hydrochloride , usp . 20 mg tablets blue , round , flat-faced , beveled edge tablet debossed 20 one side tablet blank side . available follows : bottles 30 tablets ndc 68788-8581-3 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] prevent fading , avoid exposure direct sunlight . dispense tight , light-resistant container defined usp using child-resistant closure .",
    "adverseReactions": "dicyclomine hydrochloride contraindicated infants less 6 months age [ ( 8.4 ) ] , nursing mothers [ ( 8.3 ) ] patients : \u2022unstable cardiovascular status acute hemorrhage \u2022myasthenia gravis [ ( 5.4 ) ] \u2022glaucoma [ ( 6.3 ) ( 7.1 ) ] \u2022obstructive uropathy [ ( 5.8 ) ] \u2022obstructive disease gastrointestinal tract [ ( 5.5 ) ] \u2022severe ulcerative colitis [ ( 5.7 ) ] \u2022reflux esophagitis",
    "indications_original": "Dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/ irritable bowel syndrome.",
    "contraindications_original": "Dosage must be adjusted to individual patient needs.",
    "warningsAndPrecautions_original": "Dicyclomine hydrochloride tablets, USP are available containing 20 mg of dicyclomine hydrochloride, USP.\n                  The 20 mg tablets are a blue, round, flat-faced, beveled edge tablet debossed with D 20 on one side of the tablet and blank on the other side. They are available as follows:\n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 30 tablets\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 68788-8581-3\n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]\n                  \n                  \n                     To prevent fading, avoid exposure to direct sunlight.\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.",
    "adverseReactions_original": "Dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see Use in Specific Populations (8.4)], nursing mothers [see Use in Specific Populations (8.3)] and in patients with:\n                  \n                     \n                        \u2022unstable cardiovascular status in acute hemorrhage\n                     \n                        \u2022myasthenia gravis [see Warnings and Precautions (5.4)]\n                     \n                     \n                        \u2022glaucoma [see\u00a0Adverse Reactions (6.3) and Drug Interactions (7.1)]\n                     \n                     \n                        \u2022obstructive uropathy [see Warnings and Precautions (5.8)]\n                     \n                     \n                        \u2022obstructive disease of the gastrointestinal tract [see Warnings and Precautions (5.5)]\n                     \n                     \n                        \u2022severe ulcerative colitis [see Warnings and Precautions (5.7)]\n                     \n                     \n                        \u2022reflux esophagitis"
}